MARKET

PALI

PALI

Palisade Bio Inc
NASDAQ
4.120
-0.260
-5.94%
After Hours: 4.070 -0.05 -1.21% 17:12 04/12 EDT
OPEN
4.280
PREV CLOSE
4.380
HIGH
4.570
LOW
3.820
VOLUME
63.50K
TURNOVER
0
52 WEEK HIGH
36.60
52 WEEK LOW
3.820
MARKET CAP
3.51M
P/E (TTM)
-0.1528
1D
5D
1M
3M
1Y
5Y
Palisade Bio to Participate in the Virtual Investor Lunch Break Event
Palisade Bio, Inc. Is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company will present at the Virtual Investor Lunch Break Featuring Palisade bio event on Tuesday, April 16, 2024 at 12:00 PM ET. Live webcast with members of palisade bio management.
Barchart · 1d ago
Palisade Bio stock slides 8% amid colitis drug presentation
Palisade Bio stock slides 8% amid colitis drug presentation. The company announced a presentation on its ulcerative colitisDrug candidate PALI-2108 at an industry event. Palisade conducted a 1-for-15 reverse stock split on Monday.
Seeking Alpha · 2d ago
Palisade Bio Presents Development Overview Of PALI-2108 At The IBD Innovate: Product Development For Crohn's & Colitis April 9-10, 2024 In Cambridge, MA
Palisade Bio's PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year end. Company presented at IBD Innovate: Product Development for Crohn's & Colitis.
Benzinga · 2d ago
Weekly Report: what happened at PALI last week (0401-0405)?
Weekly Report · 4d ago
Palisade Bio Plans 1-For-15 Reverse Split Of Its Common Stock
The reverse stock split is intended to increase the Company's per share trading price. The Company's Common Stock will continue to trade on The Nasdaq Capital Market on a split adjusted basis. The company's stock will trade under the trading symbol "PALI" starting April 8, 2024.
Benzinga · 04/03 21:31
PALISADE BIO ANNOUNCES 1-FOR-15 REVERSE STOCK SPLIT
Reuters · 04/03 21:30
Weekly Report: what happened at PALI last week (0325-0329)?
Weekly Report · 04/01 09:46
Analysts Are Bullish on Top Healthcare Stocks: Inventiva (IVA), Palisade Bio (PALI)
TipRanks · 03/28 14:10
More
About PALI
Palisade Bio, Inc. is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company’s approach is founded on the discovery that damage to the intestinal epithelial barrier can result in the leakage of digestive enzymes from the gastrointestinal (GI) tract into the peritoneal cavity, which can damage tissues and promote inflammation, causing a broad array of acute and chronic conditions. Its lead therapeutic candidate, LB1148, is an oral liquid formulation of the well-characterized digestive enzyme inhibitor tranexamic acid (TXA), which is being developed for administration prior to surgeries that are at risk of disrupting the intestinal epithelial barrier. LB1148 is formulated as an aqueous solution for oral (enteral) administration. In addition to TXA, the LB1148 formulation contains polyethylene glycol, carbohydrates, and electrolytes.

Webull offers Palisade Bio Inc stock information, including NASDAQ: PALI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PALI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PALI stock methods without spending real money on the virtual paper trading platform.